ReviewEuropean journal of heart failure2022
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology.
Review in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Clinic Value of Blood Urea to Creatinine Ratio in Heart Failure Patients: A Systematic Review.Clinical cardiology · 2026Pooled it
- The Role of Oxidative Stress and Inflammatory Parameters in Heart Failure.Medicina (Kaunas, Lithuania) · 2024Pooled it
- Protein S-Nitrosylation in Heart Failure: A Compartment-Resolved Review of Mechanisms, Evidence Boundaries, and Translational Perspectives.Antioxidants (Basel, Switzerland) · 2026Review
- Combined Prognostic Value of the PROFUND Index and Serum Albumin for One-Year Mortality in Elderly Patients with Acute Heart Failure.Journal of clinical medicine · 2026Article
- Tailoring heart failure management in cardiac amyloidosis.Heart failure reviews · 2026Review
- Echocardiographic Assessment of Right Ventricular-Pulmonary Arterial Coupling in Heart Failure: Prognostic Insights from a Systematic Review.Journal of clinical medicine · 2026Review
- Addressing Unmet Needs in Heart Failure with Preserved Ejection Fraction: Multi-Omics Approaches to Therapeutic Discovery.International journal of molecular sciences · 2026Review
- Surrogate Endpoints in Pivotal Clinical Trials for Drug Approval in Japan Compared to the United States.Clinical and translational science · 2025Article
- Carbohydrate antigen-125 (CA125): a marker of right ventricular dysfunction and poor prognosis in heart failure with preserved ejection fraction.International journal of cardiology. Heart & vasculature · 2025Article
- Histone H2A: a promising diagnostic marker in heart failure with reduced versus preserved ejection fraction.Molecular and cellular biochemistry · 2025Article
- Biomarkers in heart failure: Traditional and emerging indicators for prognosis.ESC heart failure · 2025Article
- Advancing efficacy prediction for electronic health records based emulated trials in repurposing heart failure therapies.NPJ digital medicine · 2025Article
- Proteomic-based biomarker discovery reveals panels of diagnostic biomarkers for early identification of heart failure subtypes.Journal of translational medicine · 2025Article
- Drug Discovery and Development for Heart Failure Using Multi-Omics Approaches.International journal of molecular sciences · 2025Review
- 2024 update in heart failure.ESC heart failure · 2025Review
- Independent and combined associations of high-density lipoprotein cholesterol-modified triglyceride-glucose index with all-cause and cardiovascular mortality in patients with acute decompensated heart failure.Frontiers in endocrinology · 2025Article
- Comprehensive Quality Analysis of Conventional and Novel Biomarkers in Diagnosing and Predicting Prognosis of Coronary Artery Disease, Acute Coronary Syndrome, and Heart Failure, a Comprehensive Literature Review.Journal of cardiovascular translational research · 2024Review
- Clustering Based on Laboratory Data in Patients With Heart Failure Admitted to the Intensive Care Unit.Journal of clinical laboratory analysis · 2024Article
- Global longitudinal strain and plasma biomarkers for prognosis in heart failure complicated by diabetes: a prospective observational study.BMC cardiovascular disorders · 2024Observational
- A Set of Possible Markers for Monitoring Heart Failure and Cognitive Impairment Associated: A Review of Literature from the Past 5 Years.Biomolecules · 2024Review
Corrections and comments
- Erratum issued
Authors and funding
27 authors at 20 institutions in 13 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The approval of new heart failure (HF) therapies has slowed over the past two decades in part due to the high costs of conducting large randomized clinical trials that are needed to adequately power major clinical endpoint studies. Several biomarkers have been identified reflecting different elements of HF pathophysiology, with possible applications in diagnosis, risk stratification, treatment monitoring, and even in the design of clinical trials. Biomarkers could potentially be used to refine study inclusion criteria to enable enrolment of patients who are more likely to respond to a therapeutic intervention, despite being at sufficient risk to meet pre-determined study endpoint rates. When there is a close relationship between biomarker levels and clinical endpoints, changes in biomarker levels after a given treatment can act as a surrogate endpoint, potentially reducing the duration and cost of a clinical trial. Natriuretic peptides have been widely used in clinical trials with a variable amount of added value, which such variation being probably due to the absence of a close pathophysiological connection to the study drug. Notable exceptions to this include sacubitril/valsartan and vericiguat. Future studies should seek to adopt unbiased approaches for discovery of true companion diagnostics; with -omics-based tools, biomarkers might be more precisely selected for use in clinical trials to identify responses that closely reflect the biological effects of the drug under investigation. Finally, biomarkers associated with cardiac damage and remodelling, such as cardiac troponin, could be employed as safety endpoints provided that standardization between different assays is achieved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.